Antimicrobial prophylaxis in hematology

Infections in Hematology

Volumn , Issue , 2015, Pages 275-296

  Girmenia, Corrado ^a   Menichetti, Francesco ^b  

^a POLICLINICO UMBERTO I   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84956709646     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-662-44000-1_16     Document Type: Chapter

References (82)

1. Schimpff SC, Young V, Greene E, et al. Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. Ann Intern Med. 1972;77:707–15.
2. Donnelly JP. Chemoprophylaxis for the prevention of bacterial and fungal infections. Cancer Treat Res. 1995;79:45–82.
3. Hawthorn JW. Critical appraisal of antimicrobials for prevention of infections in immunocompromised hosts. Hematol Oncol Clin N Am. 1993;7:1051–99.
4. Guiot HF, van den Broek J, van der Meer JW, van Furth R. Selective antimicrobial modulation of the intestinal fl ora of patients with acute nonlymphocytic leukemia: a double blind, placebocontrolled study. J Infect Dis. 1983;147:615–23.
5. Gualtieri RJ, Donowitz GR, Kaiser DL, et al. Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med. 1983;74:934–40.
6. Kramer BS, Carr DJ, Rand KH, et al. Prophylaxis of fever and infection in adult cancer patients. A placebo-controlled trial of oral trimethoprim – sulfamethoxazole plus erythromycin. Cancer. 1984;53:329–35.
7. Karp JE, Merz WG, Hendricksen C, et al. Oral norfl oxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomised double- blind, placebo-controlled trial. Ann Intern Med. 1987;106:1–7.
8. Winston DJ, Ho WG, Champlin RE, et al. Norfl oxacin for prevention of bacterial infections in granulocytopenic patients. Am J Med. 1987;82:40–6.
9. Talbot GH, Cassileth PA, Paradiso L, et al. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukaemia. The Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother. 1993;37:474–82.
10. Lew MA, Kehoe K, Ritz J, et al. Prophylaxis of bacterial infections with ciprofl oxacin in patients undergoing bone marrow transplantation. Transplantation. 1991;51:630–6.
11. Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979–95.
12. Bucaneve G, Micozzi A, Menichetti F, et al. Levofl oxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–87.
13. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988–98.
14. Bucaneve G, Castagnola E, Viscoli C, Menichetti F, Leibovici L. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer. 2007;5 Suppl 2:5–12.
15. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant. 2011;46:709–18.
16. Styczynski J, Reusser P, Einsele H, Second European Conference on Infections in Leukemia, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009;43:757–70.
17. Ljungman P, de la Camara R, Cordonnier C, European Conference on Infections in Leukemia, Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008;42:227–40.
18. Wingard JR, Carter SL, Walsh TJ, et al. Randomized double-blind trial of fl uconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111–8.
19. Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155:318–27.
20. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93.
21. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.
22. Kotilainen P, Nikoskelainen J, Houvien P. Emergence of ciprofl oxacin resistant coagulase negative staphylococcal skin fl ora in immunocompromised patients receiving ciprofl oxacin. J Infect Dis. 1990;161:41–4.
23. Trucksis M, Hooper DC, Wolfson JS. Emerging resistance to fl uoroquinolones in staphylococci: an alert. Ann Intern Med. 1991;114:424–6.
24. Kern WV, Andriof E, Oethinger M, et al. Emergence of fl uoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994;38:681–7.
25. Caratalla J, Fernandez-Sevilla A, Dominguez MA, et al. Emergence of fl uoroquinoloneresistant fl ora of cancer patients receiving norfl oxacin prophylaxis. Antimicrob Agents Chemother. 1996;40:503.
26. Cometta A, Calandra T, Bille J, et al. Escherichia coli resistant to fl uoroquinolone prophylaxis in patients with cancer and neutropenia. N Engl J Med. 1994;330:1240–1.
27. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–51.
28. Gafter-Gvili A, Paul M, Fraser A, et al. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother. 2007;59:5–22.
29. Bow EJ, Laverdière M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer. 2002;94:3230–46.
30. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and metaanalysis. J Clin Oncol. 2007;25:5471–89.
31. Girmenia C. Prophylaxis of invasive fungal diseases in patients with hematologic disorders. Haematologica. 2010;95:1630–2.
32. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24–34.
33. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs. 2009;18:1279–95.
34. Slavin MA, Osborne B, Adams R, et al. Effi cacy and safety of fl uconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–52.
35. Goodman JL, Winston DJ, Greenfi eld RA, et al. A controlled trial of fl uconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–51.
36. Marr K, Seidel K, Slavin M, et al. Prolonged fl uconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96:2055–61.
37. Schaffner A, Schaffner M. Effect of prophylactic fl uconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis. 1995;172:1035–41.
38. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebocontrolled trial of fl uconazole prophylaxis for neutropenic cancer patients: benefi t based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis. 1999;28:331–40.
39. Glasmacher A, Prentice A, Gorschlüter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a metaanalysis of 3,597 patients. J Clin Oncol. 2003;21:4615–26.
40. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fl uconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138:705–13.
41. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fl uconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527–33.
42. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fl uconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother. 2006;57:317–25.
43. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:696–709.
44. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:662–78.
45. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fl uconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–59.
46. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fl uconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–47.
47. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fl uconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407–16.
48. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50:143–7.
49. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46:1401–8.
50. Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother. 2009;53:1793–6.
51. Girmenia C, Aversa F, Micozzi A. Voriconazole prophylaxis and the risk of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 4 February 2011, e-letter for Wingard Blood. 2010;116:5111–8.
52. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.
53. Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2006;108:2928–36.
54. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the effi cacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis. 2006;42:1584–91.
55. Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in patients with allogeneic stem cell transplants (VOSIFI) study group; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95:1762–8.
56. Girmenia C. Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients (reply). Haematologica. 2011;96:e11.
57. Girmenia C, Barosi G, Piciocchi A, et al. Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20:1080–8.
58. Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo(GITMO). Biol Blood Marrow Transplant. 2014;20:872–80.
59. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052–9.
60. Gratwohl A, Brand R, Frassoni F, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 2005;36:757–69.
61. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593–602.
62. Maltezou HC, Kafetzis DA, Abisaid D, et al. Viral infections in children undergoing hematopoietic stem cell transplant. Pediatr Infect Dis J. 2000;19:307–12.
63. Sandherr M, Einsele H, Hebart H, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol. 2006;17:1051–9.
64. Rossi G, Pelizzari A, Motta M, et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115:58–62.
65. Yeo W, Chan P, Ho WM, et al. Lamivudine for the prevention of Hepatitis B Virus reactivation in Hepatitis B s-Antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22:927–34.
66. Locasciulli A, Testa M, Valsecchi MG, et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation. 1999;68:1486–91.
67. Chiba T, Yokosuka O, Goto S, et al. Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: benefi cial combination of adoptive immunity transfer and lamivudine. Eur J Haematol. 2003;71:220–3.
68. Locasciulli A, Alberti A, Bandini G, et al. Allogeneic bone marrow transplantation from HbsAg+ donors: a multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 1995;86:3236–40.
69. Weinstock DM, Boeckh M, Boulad F, et al. Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. Infect Control Hosp Epidemiol. 2004;25:603–8.
70. Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation (see comments). Blood. 1999;94:4029–35.
71. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identifi cation and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1–20.
72. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–9.
73. Hsu C, Hsiung CA, Su I-J, et al. A revisit of prophylactic lamivudine for chemotherapyassociated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47:844–53.
74. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006;24:1003–9. 82.
75. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008;15:89–102.
76. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic stem cell transplantation. Hepatology. 2002;36:702–9.
77. Hui CK, Lie A, Au W-Y, et al. Effectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant. 2005;5:1437–45.
78. Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible effi cacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin’s lymphoma. Ann Hematol. 2004;83:58–60.
79. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23.
80. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol. 2010;25:864–71.
81. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–22.
82. Kim JS, Hahn JS, Park SY, et al. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin’s lymphoma. Yonsei Med J. 2007;48:78–89.